Arbutus Biopharma Corp
ABUS- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001447028
No open-market purchases or sales by Arbutus Biopharma Corp insiders were filed in the last 90 days; 176 institutions reported holding it in 13F filings for Q2 2026, worth $674.9M in total; no superinvestor holds it.
13F holders, Q3 2023
Institutional positions in Arbutus Biopharma Corp as of Sep 30, 2023. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 99
- −11 vs. Q2 2023
- Shares held
- 70.8M
- +4.61M (+7.0%) vs. Q2 2023
- Total value
- $143.8M
- −$8.59M (−5.6%) vs. Q2 2023
- New holders
- 5
- 36 more added
- Sold out
- 16
- 23 more reduced
1 institution that held it in Q2 2023 haven't filed for Q3 2023 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.
Compare with Q2 2023: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting ABUS on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 176 | $674.9M |
| Q1 2026 | 167 | $625.4M |
| Q4 2025 | 172 | $586.9M |
| Q3 2025 | 166 | $536.4M |
| Q2 2025 | 163 | $365.0M |
| Q1 2025 | 168 | $390.1M |
| Q4 2024 | 154 | $340.3M |
| Q3 2024 | 144 | $389.2M |
| Q2 2024 | 131 | $298.4M |
| Q1 2024 | 119 | $215.2M |
| Q4 2023 | 112 | $197.4M |
| Q3 2023 | 99 | $143.8M |
| Q2 2023 | 111 | $152.4M |
| Q1 2023 | 122 | $189.3M |
| Q4 2022 | 114 | $126.3M |
| Q3 2022 | 127 | $89.1M |
| Q2 2022 | 113 | $120.0M |
| Q1 2022 | 119 | $130.6M |
| Q4 2021 | 123 | $154.4M |
| Q3 2021 | 100 | $149.8M |
| Q2 2021 | 91 | $87.6M |
| Q1 2021 | 94 | $86.5M |
Institutions, Q3 2023
Shares, value and share of portfolio for each institution holding Arbutus Biopharma Corp; share changes are against Q2 2023.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Rubric Capital Management LP | 0 | $0 | 0.00% | −3,395,855−100.0% | Sold out |
| Primecap Management Co | 0 | $0 | 0.00% | −328,100−100.0% | Sold out |
| Renaissance Technologies LLC | 0 | $0 | 0.00% | −321,128−100.0% | Sold out |
| DekaBank Deutsche Girozentrale | 0 | $0 | 0.00% | −150,000−100.0% | Sold out |
| Gsa Capital Partners LLP | 0 | $0 | 0.00% | −36,923−100.0% | Sold out |
| Man Group plc | 0 | $0 | 0.00% | −24,500−100.0% | Sold out |
| Prelude Capital Management, LLC | 0 | $0 | 0.00% | −18,790−100.0% | Sold out |
| Two Sigma Advisers, LP | 0 | $0 | 0.00% | −13,700−100.0% | Sold out |
| Credit Agricole S A | 0 | $0 | 0.00% | −7,750−100.0% | Sold out |
| Allworth Financial LP | 0 | $0 | 0.00% | −440−100.0% | Sold out |
| Richard W. Paul & Associates, LLC | 0 | $0 | 0.00% | −379−100.0% | Sold out |
| Key Financial Inc | 0 | $0 | 0.00% | −322−100.0% | Sold out |
| Allspring Global Investments Holdings, LLC | 0 | $0 | 0.00% | −95−100.0% | Sold out |
| Crewe Advisors LLC | 0 | $0 | 0.00% | −56−100.0% | Sold out |
| GWM Advisors LLC | 0 | $0 | 0.00% | −10−100.0% | Sold out |
| Coastal Capital Group, Inc. | – | – | – | – | Not filed |